Compare iShares MSCI Malaysia ETF (EWM) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Malaysia ETF vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? iShares MSCI Malaysia ETF trades at $26.86 (market cap $242.56M), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M). The key difference: Maravai LifeSciences Holdings Inc. Class A Common Stock is far larger — about 4× iShares MSCI Malaysia ETF's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, iShares MSCI Malaysia ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Malaysia ETF for 68 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| EWM | MRVI | |
|---|---|---|
Market Cap | $242.56M | $977.37M |
Volume | 361,558 | 2,742,564 |
Sector | Broad Market / Factor | Health |
52-Week High | $30.42 | $9.00 |
52-Week Low | $25.47 | $2.83 |
Typical Hold Time | 68 Days | 0 Days |
Enterprise Value | — | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWM trades at $26.96, up 0.63% today, but technical indicators signal a bearish trend with moving averages and ADX suggesting selling pressure. Key financial ratios like P/E and P/S are unavailable, limiting fundamental clarity. Recent news highlights external risks, such as regional haze-related disruptions affecting operations in Malaysia, which could impact investor confidence.
The outlook remains cautious due to weak technicals and limited fundamental data. Risks include environmental disruptions and market volatility. Investment opportunities hinge on upcoming financial disclosures to validate growth prospects, while current sentiment leans bearish amid uncertainty.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares MSCI Malaysia ETF
EWM tracks the MSCI Malaysia Index, providing exposure to the Malaysian equity market. It offers a diversified portfolio of large and mid-sized companies across various sectors in Malaysia.
Read more on EWM →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
